Key insights
- LivaNova (LIVN) stock has surged 65.0% over the past year, outperforming its peers, due to rising surgical procedure volumes. While this trend is hurting health insurers, it's driving steady, high-margin demand for LivaNova's cardiopulmonary and neuromodulation devices. The company benefits from essential procedures and entrenched market share, ensuring recurring sales insulated from insurer reimbursement pressures. Despite the rally, its valuation appears attractive relative to near-term earnings growth.

Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Investing.com — Managed care health insurers have spent the year getting hammered by surging medical cost ratios and elevated procedure utilization, leading many investors to avoid healthcare stocks altogether. Device makers have not escaped either: LivaNova’s InvestingPro peer group, which includes Abbott Laboratories (NYSE:ABT), Boston Scientific (NYSE:BSX), and Medtronic (NYSE:MDT), has posted a 19.1% one-year total return loss. Yet LivaNova PLC (NASDAQ:LIVN)—the maker of heart-lung machines and epilepsy implants—has returned 65.0% over the same period, including a 15.64% surge since November 1 to $91.32.
LivaNova is winning from the same trend that is hurting insurers: the rise in surgical procedures squeezing insurer margins is driving steady, high-margin device demand for its cardiopulmonary and neuromodulation platforms. Even after the rally, the shares trade at 20.6 times 2026 earnings estimates, a multiple that InvestingPro’s health checks flag as low relative to near-term earnings growth.
Catching the moment rising procedure volumes are turning into recurring device sales is what ProPicks AI is built for. In Healthcare Heroes, InvestingPro’s strategy dedicated to high-conviction healthcare stocks, LivaNova is held alongside other top November gainers—including a global oncology biotech up 12.5% this month, a medical device and orthopedics leader, and a hospital operator up 54% since selection.
LivaNova makes its money on procedures hospitals cannot postpone. It holds entrenched market share in the heart-lung machines and oxygenators used during open-heart surgery, alongside vagus nerve stimulation implants for drug-resistant epilepsy. Because hospitals cannot defer cardiac surgeries, and replacing installed operating-room hardware requires extensive clinical retraining, LivaNova enjoys recurring consumable sales insulated from insurer reimbursement battles.
Third-quarter results, reported November 4, proved how much of that demand is reaching the income statement. Revenue climbed to $393.1 million from $358 million a year earlier, topping the consensus estimate by $12 million, and adjusted EPS of $1.23 beat expectations by 16.0%. Operating income expanded to $66 million from $60 million, and EBITDA rose to $81 million from $72 million. The stock jumped 14.07% the next day, from $79.90 to $91.14, and management carried the same message through the Wolfe Research, Stifel, and UBS healthcare conferences in mid-November: growth is broadening across its core units.
That growth converts into cash. Operating cash flow reached $238 million over the trailing twelve months, with free cash flow of $129 million, and LivaNova has used it to cut total debt to $357 million from $487 million a year earlier while holding $563 million in cash and short-term investments.
Analysts see another 15% of upside even after the rally. The 11 analysts covering LivaNova hold an average price target of $105.09, with targets ranging from $75 to $120, and they project EPS of $4.43 in 2026—up 13.7%—climbing to $4.73 in 2027 and $5.18 in 2028.
InvestingPro’s Fair Value models take a more conservative line, placing intrinsic value at $92.36 per share, just 1.1% above the current price and well below the Street’s average target. After a one-year run that has taken the shares from a 52-week low of $52.37 to 91.9% of their $99.38 high, Fair Value treats the November rally as already reflected in the price.
The main risk is that estimates are now moving the wrong way. Nine analysts have cut their forecasts for the upcoming quarter over the past 90 days, leaving fourth-quarter EPS expectations 4.5% lower than a year ago, and forecast EPS growth slows to 6.7% in 2027. Free cash flow also slipped to $43 million in the third quarter from $62 million a year earlier, even as revenue grew.
Before buying a 16% two-week jump, investors must weigh LivaNova’s entrenched operating-room franchise against falling near-term estimates and a share price already near Fair Value. Cardiopulmonary consumable pricing, neuromodulation growth rates, and operating margin expansion targets are detailed inside the LivaNova InvestingPro financial models.
The same procedure boom punishing insurers is lifting a device supplier whose hardware is already installed in operating rooms. Its next test arrives with fourth-quarter results on February 24, when investors will see whether the growth broadening across its core units can outrun the estimate cuts now piling up.
Relying on a single medical device stock while insurers absorb surging procedure costs leaves capital exposed to a sector-wide healthcare sell-off. Rather than attempting to separate squeezed insurers from the device suppliers monetizing rising procedure volumes manually, InvestingPro’s data-driven strategies evaluate thousands of balance sheets every month to isolate medical operators converting clinical demand into steady free cash flow.
For investors seeking high-conviction ideas in the active November lineup, full access to all ProPicks AI strategies costs just $9 a month.
Disclosure: The author holds no position in the stocks mentioned. Data and financial metrics as of November 16, 2026.
The fastest way to find out is looking at our Fair Value estimate. It runs 17 proven valuation models on LIVN and gives you one number, plus the upside or downside against today’s price. Do the same for thousands of other stocks and you stop guessing which ones are already priced for perfection. 370,000+ investors rely on powerful InvestingPro tools from Investing.com to validate their trading ideas . Full access now 55% off for Black Friday early birds.